ClinicalTrials.gg
CompletedNCT00805194Updated Dec 5, 2018Results posted

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

A Phase 3 interventional study of placebo plus docetaxel and BIBF 1120 plus docetaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 210 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-05.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.

Enrollment
Largest of 19
1,314 · median 16
Started
2008
with 1 other
Phase 3
3 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
10 of 19
Boehringer Ingelheim

Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment, is one of 2 that started in 2008, is one of 3 in phase 3, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female patient aged 18 years or older;
  • or cytologically confirmed, locally advanced and/or NSCLC of stage IIIB or IV or recurrent NSCLC;
  • relapse or failure of one prior chemotherapy;
  • at least one target tumour lesion that has not been irradiated within the past three months and that can accurately be measured ;
  • of at least three months;
  • (ECOG) score of 0 or 1;
  • patient has given written

Exclusion criteria

Exclusion criteria:

  • more than one prior chemotherapy regimen for advanced and/or or recurrent NSCLC;
  • more than one chemotherapy treatment regimen (either or adjuvant or neoadjuvant plus adjuvant) prior to chemotherapy;
  • previous therapy with other VEGFR inhibitors (other than bevacizumab) or docetaxel for treatment of NSCLC;
  • persistence of therapy related toxicities from previous chemotherapy and/or radiotherapy;
  • treatment with other drugs or other anti-cancer therapy or treatment in another clinical trial within the past four weeks before start of - therapy or concomitantly with this trial ;
  • radiotherapy (except extremities and brain) within the past three months prior to baseline imaging;
  • active or ;
  • radiographic evidence of cavitary or necrotic tumours;
  • centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels;
  • history of clinically significant haemoptysis within the past 3 months;
  • therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy;
  • history of major thrombotic or clinically relevant major bleeding event in the past 6 months;
  • known inherited predisposition to bleeding or thrombosis;
  • significant cardiovascular diseases ;
  • inadequate safety laboratory parameters;
  • significant weight loss (> 10 %) within the past 6 weeks;
  • current peripheral neuropathy greater than grade 2 except due to trauma;
  • preexisting ascites and/or clinically significant pleural effusion;
  • major injuries and/or surgery within the past ten days prior to randomisation with incomplete wound healing;
  • serious infections requiring systemic antibiotic therapy;
  • decompensated diabetes mellitus or other to high dose therapy;
  • gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug;
  • active or chronic and/or B infection;
  • serious illness or concomitant non-oncological disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration;
  • patients who are sexually active and unwilling to use a medically acceptable method of during the trial and for at least twelve months after end of active therapy;
  • pregnancy or breast feeding;
  • psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule;
  • patients unable to comply with the protocol;
  • active alcohol or drug abuse;
  • other within the past three years other than basal cell skin cancer, or carcinoma in situ of the cervix;
  • any contraindications for therapy with docetaxel;
  • history of severe reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80);
  • hypersensitivity to BIBF 1120 and/or the of the trial drugs;
  • hypersensitivity to contrast media
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,314 participants (actual)

Study arms

  • Experimental
    BIBF 1120 plus docetaxel

    BIBF 1120 2 times daily along with standard therapy of docetaxel

    Drug: BIBF 1120 plus docetaxel

  • Placebo comparator
    Placebo plus docetaxel

    Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel

    Drug: placebo plus docetaxel

Interventions

  • Drugplacebo plus docetaxel

    placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel

  • DrugBIBF 1120 plus docetaxel

    Drug pages: Nintedanib · Docetaxel

    BIBF 1120 2 times daily along with standard therapy of docetaxel

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by Central Independent Review

    Progression Free Survival (PFS) as assessed by central independent review according to the modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) . Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)

Secondary outcomes

  1. Overall Survival (Key Secondary Endpoint)

    Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. A fixed-sequence-testing was implemented for key secondary endpoint if both the primary and the follow-up analysis showed a treatment benefit (P\<0.05) of nintedanib over placebo. In this case, the OS would be tested using hierarchical testing of statistical hypotheses in (1) patients with adenocarcinoma and \<9 months since start of first-line therapy, (2) patients with adenocarcinoma, and (3) all patients. Each hypothesis could be only tested at the pre-specified alpha level if the previous null hypothesis in the testing sequence had been.

    Time frame: From randomisation until cut-off date 15 February 2013 (approximately 48 months or 1151 deaths among all patients )

  2. Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review

    Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until cut-off date 15 February 2013

  3. Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator

    Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until cut-off date 15 February 2013

  4. Objective Tumour Response

    Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until cut-off date 15 February 2013

  5. Duration of Confirmed Objective Tumour Response

    The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until cut-off date 15 February 2013

  6. Time to Confirmed Objective Tumour Response

    Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until cut-off date 15 February 2013

  7. Disease Control

    Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0. As per RECIST v1.0 for target lesions : Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until cut-off date 15 February 2013

  8. Duration of Disease Control

    The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until cut-off date 15 February 2013

  9. Change From Baseline in Tumour Size

    Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator.

    Time frame: From randomisation until cut-off date 15 February 2013

  10. Clinical Improvement

    Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

    Time frame: From randomisation until cut-off date 15 February 2013

  11. Quality of Life (QoL)

    Quality of life (QoL) was measured by standardised questionnaires (Health Status Self-Assessment Questionnaire (EQ-5D), EORTC Quality of life questionnaire - Core 30 (EORTC QLQ-C30), Quality of life questionnaire - lung cancer module (EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (EORTC QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve

    Time frame: From randomisation until cut-off date 15 February 2013

  12. Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide

    Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.

    Time frame: Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3

  13. Incidence and Intensity of Adverse Events

    Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used. Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.

    Time frame: From the first drug administration until 28 days after the last drug administration, up to 42 months

07

Results

Posted Dec 1, 2014

Participant flow

Participant flow — Overall Study
MilestoneNintedanib Plus DocetaxelPlacebo Plus Docetaxel
Started655659
Completed65
Not completed649654
Withdrew: Progressive disease (modified recist)404435
Withdrew: Worsening or ae of underlying disease6470
Withdrew: Other ae8473
Withdrew: Protocol violation99
Withdrew: Lost to follow-up55
Withdrew: Withdrawal by subject6042
Withdrew: Not treated34
Withdrew: Reasons other than stated above2016

Outcome measures

PrimaryProgression Free Survival (PFS) as Assessed by Central Independent Review

Progression Free Survival (PFS) as assessed by central independent review according to the modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) . Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)
Reported as:
Median · months
Progression Free Survival (PFS) as Assessed by Central Independent Review
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
Progression Free Survival (PFS) as Assessed by Central Independent Review3.4 (1.5 to 5.7)2.7 (1.4 to 4.6)
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.0019 · Hazard ratio (hr): 0.79 · 95% CI 0.68 to 0.92Hazard Ratio (HR) below 1 favors nintedanib
SecondaryOverall Survival (Key Secondary Endpoint)

Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. A fixed-sequence-testing was implemented for key secondary endpoint if both the primary and the follow-up analysis showed a treatment benefit (P\<0.05) of nintedanib over placebo. In this case, the OS would be tested using hierarchical testing of statistical hypotheses in (1) patients with adenocarcinoma and \<9 months since start of first-line therapy, (2) patients with adenocarcinoma, and (3) all patients. Each hypothesis could be only tested at the pre-specified alpha level if the previous null hypothesis in the testing sequence had been.

Time frame:
From randomisation until cut-off date 15 February 2013 (approximately 48 months or 1151 deaths among all patients )
Reported as:
Median · months
Overall Survival (Key Secondary Endpoint)
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
Adenocarcinoma and <9 months10.9 (5.1 to 21.9)7.9 (4.5 to 14.5)
Adenocarcinoma12.6 (5.5 to 24.2)10.3 (5.5 to 19.9)
All patients10.1 (5.0 to 19.4)9.1 (4.8 to 17.2)
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.0073 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs 1 - one pat. had 2), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.75 · 95% CI 0.60 to 0.92The overall alpha level followed a Lan-DeMets spending function with O'Brien-Fleming shape parameter to preserve an overall 2-sided alpha level of 0.05. HR below 1 favors nintedanib
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.0359 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs 1 - one pat. had 2), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.83 · 95% CI 0.70 to 0.99The overall alpha level followed a Lan-DeMets spending function with O'Brien-Fleming shape parameter to preserve an overall 2-sided alpha level of 0.05. HR below 1 favors nintedanib
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.2720 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs 1 - one pat. had 2), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.94 · 95% CI 0.83 to 1.05The overall alpha level followed a Lan-DeMets spending function with O'Brien-Fleming shape parameter to preserve an overall 2-sided alpha level of 0.05. HR below 1 favors nintedanib
SecondaryFollow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review

Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review3.5 (1.5 to 5.7)2.7 (1.4 to 5.5)
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.0070 (HR, CI and p-value obtained from the proportional hazards model stratified by baseline ECOG PS (0 vs 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.85 · 95% CI 0.75 to 0.96HR below 1 favors nintedanib
SecondaryFollow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator

Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator4.2 (2.1 to 7.1)3.0 (1.4 to 5.7)
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.0012 (HR, CI and p-value obtained from the proportional hazards model stratified by baseline ECOG PS (0 vs 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.82 · 95% CI 0.73 to 0.93HR below 1 favors nintedanib
SecondaryObjective Tumour Response

Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Number · % of participants
Objective Tumour Response
% of participantsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
central independent reviewer4.43.3
investigator assessment10.47.6
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Logistic · p = 0.3067 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.34 · 95% CI 0.76 to 2.39An odds ratio \>1 indicates a benefit to nintedanib
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Logistic · p = 0.0761 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.41 · 95% CI 0.96 to 2.08An odds ratio \>1 indicates a benefit to nintedanib
SecondaryDuration of Confirmed Objective Tumour Response

The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Duration of Confirmed Objective Tumour Response
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
central independent reviewer4.3 (3.0 to 5.7)4.3 (2.8 to 8.5)
investigator assessment5.7 (4.1 to 10.0)5.5 (3.9 to 9.6)
SecondaryTime to Confirmed Objective Tumour Response

Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Time to Confirmed Objective Tumour Response
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
central independent reviewer1.5 (1.4 to 3.0)2.9 (1.4 to 5.6)
investigator assessment2.6 (1.4 to 4.0)2.7 (1.4 to 4.1)
SecondaryDisease Control

Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0. As per RECIST v1.0 for target lesions : Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Number · % of participants
Disease Control
% of participantsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
central independent reviewer54.041.3
investigator assessment63.451.4
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Logistic · p = <0.0001 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.68 · 95% CI 1.35 to 2.09An odds ratio \>1 indicates a benefit to nintedanib
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Logistic · p = <0.0001 (Odds ratio and p-value are obtained from logistic regression model adjusted for baseline ECOG PS (0 vs 1)) · Odds ratio (or): 1.64 · 95% CI 1.31 to 2.05An odds ratio \>1 indicates a benefit to nintedanib
SecondaryDuration of Disease Control

The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Duration of Disease Control
monthsNintedanib Plus DocetaxelPlacebo Plus Docetaxel
central independent reviewer5.6 (4.1 to 7.1)5.6 (4.0 to 8.2)
investigator assessment5.7 (4.2 to 8.4)5.6 (4.1 to 8.5)
SecondaryChange From Baseline in Tumour Size

Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Mean · percentage of change in tumor size in mm
Change From Baseline in Tumour Size
percentage of change in tumor size in mmNintedanib Plus DocetaxelPlacebo Plus Docetaxel
central independent reviewer-4.87 (-6.62 to -3.12)0.58 (-1.19 to 2.35)
investigator assessment-10.34 (-12.58 to -8.11)-2.14 (-4.39 to 0.10)
Statistical analysis
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · ANOVA · p = <0.0001 (P-value generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no))
  • Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel · ANOVA · p = <0.0001 (P-value generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no))
SecondaryClinical Improvement

Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Clinical Improvement
monthsNitedanib Plus DocetaxelPlacebo Plus Docetaxel
Clinical Improvement5.9 (2.1 to 22.7)5.2 (2.1 to 19.2)
Statistical analysis
  • Nitedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.7282 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs 1 - one pat.had 2), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 1.03 · 95% CI 0.87 to 1.21HR below 1 favors nintedanib
SecondaryQuality of Life (QoL)

Quality of life (QoL) was measured by standardised questionnaires (Health Status Self-Assessment Questionnaire (EQ-5D), EORTC Quality of life questionnaire - Core 30 (EORTC QLQ-C30), Quality of life questionnaire - lung cancer module (EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (EORTC QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve

Time frame:
From randomisation until cut-off date 15 February 2013
Reported as:
Median · months
Quality of Life (QoL)
monthsNitedanib Plus DocetaxelPlacebo Plus Docetaxel
Time to deterioration of cough4.3 (1.6 to 11.8)3.5 (1.5 to 12.6)
Time to deterioration of dyspnoea2.0 (0.8 to 4.2)2.1 (0.8 to 4.5)
Time to deterioration of pain2.8 (1.1 to 6.5)2.6 (0.8 to 5.8)
Statistical analysis
  • Nitedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.1858 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs \>=1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.90 · 95% CI 0.77 to 1.05HR below 1 favors nintedanib
  • Nitedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.5203 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs \>=1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 1.05 · 95% CI 0.91 to 1.20HR below 1 favors nintedanib
  • Nitedanib Plus Docetaxel vs Placebo Plus Docetaxel · Regression, Cox · p = 0.4373 (HR, CI and p-value obtained from the prop. hazards model stratified by baseline ECOG PS (0 vs \>= 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)) · Hazard ratio (hr): 0.95 · 95% CI 0.82 to 1.09HR below 1 favors nintedanib
SecondaryDose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide

Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.

Time frame:
Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3
Reported as:
Geometric mean · ng/mL/mg
Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide
ng/mL/mgNitedanib 200 mg Bid Plus DocetaxelNintedanib 150 Bid mg Plus Docetaxel
nintedanib0.0707 ± 77.70.106 ± 52.6
metabolite BIBF 12020.0907 ± 1270.190 ± 152
metabolite BIBF 1202 glucuronide1.04 ± 1531.94 ± 135
SecondaryIncidence and Intensity of Adverse Events

Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used. Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.

Time frame:
From the first drug administration until 28 days after the last drug administration, up to 42 months
Reported as:
Number · % of participants
Incidence and Intensity of Adverse Events
% of participantsNitedanib Plus DocetaxelPlacebo Plus Docetaxel
Grade 15.78.2
Grade 216.620.5
Grade 321.221.2
Grade 433.731.3
Grade 516.411.8

Adverse events

Collected over From the first drug administration until 28 days after the last drug administration, up to 42 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib Plus Docetaxel107/652 (16.4%)224/652 (34.4%)569/652 (87.3%)
Placebo Plus Docetaxel77/655 (11.8%)206/655 (31.5%)547/655 (83.5%)
Most frequent serious events
Showing 10 of 232
Most frequent serious events
EventNintedanib Plus DocetaxelPlacebo Plus Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders30/65219/655
DyspnoeaRespiratory, thoracic and mediastinal disorders24/65230/655
PneumoniaInfections and infestations17/65226/655
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)25/65217/655
NeutropeniaBlood and lymphatic system disorders21/65221/655
DiarrhoeaGastrointestinal disorders16/65213/655
General physical health deteriorationGeneral disorders11/6528/655
PyrexiaGeneral disorders7/6529/655
VomitingGastrointestinal disorders8/6527/655
Pleural effusionRespiratory, thoracic and mediastinal disorders8/6528/655
Most frequent other events
Showing 10 of 32
Most frequent other events
EventNintedanib Plus DocetaxelPlacebo Plus Docetaxel
DiarrhoeaGastrointestinal disorders260/652130/655
Neutrophil count decreasedInvestigations236/652232/655
FatigueGeneral disorders191/652175/655
Alanine aminotransferase increasedInvestigations184/65255/655
NauseaGastrointestinal disorders158/652117/655
White blood cell count decreasedInvestigations157/652158/655
Aspartate aminotransferase increasedInvestigations145/65243/655
Decreased appetiteMetabolism and nutrition disorders144/652101/655
AlopeciaSkin and subcutaneous tissue disorders107/652119/655
CoughRespiratory, thoracic and mediastinal disorders96/652108/655

Baseline characteristics

Randomised Set (RS)- Includes all randomised patients, whether patients had received study treatment or not

Age, Continuous
Age, Continuous(years)Nintedanib Plus DocetaxelPlacebo Plus DocetaxelTotal
Mean59.7 ± 9.759.8 ± 9.059.7 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib Plus DocetaxelPlacebo Plus DocetaxelTotal
Female179180359
Male476479955
Tumour histology
Tumour histology(Participants)Nintedanib Plus DocetaxelPlacebo Plus DocetaxelTotal
Adenocarcinoma322336658
Squamous cell carcinoma276279555
Other5744101
Number of patients with adenocarcinoma and time since first line therapy in categories
Number of patients with adenocarcinoma and time since first line therapy in categories(Participants)Nintedanib Plus DocetaxelPlacebo Plus DocetaxelTotal
<9 month206199405
>=9 month112134246
Missing437
08

Study locations

210 sites
  • LKH-Univ. Hospital Graz
    Graz, 8036, Austria
  • KH St. Vinzenz, Zams, Int. Abtlg.
    Kufstein, 6330, Austria
  • AKH d. Stadt Linz, Pulmologie
    Linz, 4020, Austria
  • Bobruisk Inter-distict
    Bobruisk, 213825, Belarus
  • Brest Regional Clinical
    Brest Region, 224027, Belarus
  • Gomel Regional Clinical
    Gomel, 246012, Belarus
  • Scientific Research Minsk
    Minsk Region, 223040, Belarus
  • Public Health Inst. Minsk City Clinical Oncology Dispensary
    Minsk, 220013, Belarus
  • Mogilov Regional Oncological Dispensary
    Mogilov, 212018, Belarus
  • Vitebsk Regional Clinical Oncology Dispensary
    Vitebsk, 210603, Belarus
  • Centre Hospitalier Universitaire de Liège
    Liège, 4000, Belgium
  • Liège - HOSP CHR de la Citadelle
    Liège, 4000, Belgium
  • Multiprofile Hospital for Active Treatment
    Gabrovo, 5300, Bulgaria
  • Univ.Multiprofile Hospital "Dr. Georgy Stranski" EAD, Pleven
    Pleven, 5800, Bulgaria
  • District Oncology Dispensary Plovdiv
    Plovdiv, 4004, Bulgaria
  • Interdistrict Oncology Dispensary, Ruse
    Ruse, 7002, Bulgaria
  • District Oncology Dispensary Shumen
    Shumen, 9700, Bulgaria
  • Specialized Hospital for Active Treatment in Oncolcogy
    Sofia, 1756, Bulgaria
  • 307 Hospital of PLA
    Beijing, 100071, China
  • Jilin Province Cancer Hospital
    Changchun, 130012, China
  • First Hospital of Jilin University
    Changchun, 130021, China
  • West China Hospital
    Chengdu, 610041, China
  • Southwest Hospital
    Chongqing, 400038, China
  • First Affiliated Hospital of Dalian Medical University
    Dalian, 116011, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, 116027, China
  • Fujian Provincial Tumor Hospital
    Fujian, 350014, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, 510060, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • Sir Run Run Shaw Hospital
    Hangzhou, 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • The Third Affiliated Hospital of Harbin Medical University
    Harbin, 150081, China
  • the 81th Hospital of PLA
    Nanjing, 210002, China
  • Jiangsu Cancer Hospital
    Nanjing, 210009, China
  • Shanghai Chest Hospital
    Shanghai, 200030, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • Tongji Hospital, Tongji University
    Wuhan, 430030, China
  • Zhongshan Hospital Fudan University
    Xuhui Area, Shanghai, 200032, China
  • Clinical Hospital Centar Sestre Milosrdnice
    Zagreb, 10000, Croatia
  • UHC Zagreb
    Zagreb, 10000, Croatia
  • University Hospital Brno
    Brno, 625 00, Czechia
  • St. Anna Hospital, 2nd Internal Department
    Brno, 656 53, Czechia
  • District Hospital Liberec
    Liberec, 460 01, Czechia
  • Institut onkologie a rehabilitace Na Plesi s.r.o.
    Nova Ves pod Plesi, 262 04, Czechia
  • District Hospital Pribram, Oncology Centrum
    Pribram, 261 95, Czechia
  • Herlev Hospital
    Herlev, 2730, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • HOP Croix Rousse, Pneumo, Lyon
    Lyon Cedex 4, 69317, France
  • INS Paoli-Calmettes
    Marseille Cedex 9, 13273, France
  • HOP Lyon Sud
    Pierre Bénite cedex, 69495, France
  • CHU de Rouen - Hôpital de Bois Guillaume
    ROUEN cedex, 76031, France
  • HOP Nord Laënnec
    Saint Herblain cedex, 44805, France
  • Oncology Institute of the Loire
    Saint-Priest en Jarez, 42271, France
  • HOP Civil
    Strasbourg cedex, 67091, France
  • Sainte Anne Training hospital for the armies
    Toulon Cedex 09, 83401, France
  • Amtel Hospital first Clinical LLC
    Tbilisi, 0079, Georgia
  • National Centre of Oncology
    Tbilisi, 0177, Georgia
  • Chemotherapy & Immunotherapy Clinic 'Medulla', Tbilisi
    Tbilisi, 0186, Georgia
  • Gemeinschaftspraxis Dr. Brudler / Dr. Heinrich, Augsburg
    Augsburg, 86150, Germany
  • Zentralklinik Bad Berka GmbH
    Bad Berka, 99437, Germany
  • Evangelische Lungenklinik Berlin
    Berlin-Buch, 13125, Germany
  • Universitätsklinikum Benjamin Franklin, Berlin
    Berlin, 12200, Germany
  • Helios Klinikum Emil von Behring
    Berlin, 14165, Germany
  • Krankenhaus Nordwest, Frankfurt
    Frankfurt/Main, 60488, Germany
  • Klinikum Frankfurt Höchst GmbH
    Frankfurt/Main, 65929, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Asklepios Fachkliniken München-Gauting
    Gauting, 82131, Germany
  • Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH
    Großhansdorf, 22927, Germany
  • Krankenhaus Martha-Maria Halle-Dölau gGmbH
    Halle/Saale, 06120, Germany
  • Allgemeines Krankenhaus Harburg, 21075 Hamburg
    Hamburg, 21075, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • Klinikum Kassel GmbH
    Kassel, 34125, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Kiel, 24116, Germany
  • Gemeinschaftspraxis für Hämatologie und Onkologie, Köln
    Köln, 50677, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • POIS Leipzig GbR
    Leipzig, 04357, Germany
  • Klinik, Löwenstein
    Löwenstein, 74245, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Kiel
    Lübeck, 23538, Germany
  • Katholisches Klinikum St. Hildegardiskrankenhaus, Mainz
    Mainz, 55131, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, D-55131, Germany
  • Universitätsklinik links der Isar, München, Ziemssenstr. 1
    München, 80336, Germany
  • Klinikum rechts der Isar der Technischen Universität München
    München, 81675, Germany
  • Städt. Krankenhaus, München-Bogenhausen
    München, 81925, Germany
  • Pius-Hospital, Oldenburg
    Oldenburg, 26121, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Helios Dr. Horst Schmidt Kliniken Wiesbaden
    Wiesbaden, 65199, Germany
  • Evangelisches Krankenhaus, Witten
    Witten, 58455, Germany
  • Athens Hospital of Chest Diseasea "SOTIRIA"
    Athens, 11527, Greece
  • University Hospital of Heraklion, University Pulmonology Cl
    Heraklio, 71110, Greece
  • Iaso General Hospital
    Holargos, Athens, 15562, Greece
  • Papageorgiou Hospital, 1st Cardiological Cl., Thessaloniki
    Thessaloniki, 54603, Greece
  • General Hospital of Thessaloniki "G. Papanikolaou"
    Thessaloniki, 57010, Greece
  • Vedanta Institute of Medical Sciences
    Ahmedabad, 380009, India
  • KIDWAI memoraial Institute of oncology
    Bangalore, 560029, India
  • Rajalakshmi Multispeciality Hospital
    Bangalore, 560078, India
  • Jawaharlal Nehru Cancer Hospital & Research Centre
    Bhopal, M.P., 462001, India
  • Apollo Hospital
    Chennai, 600035, India
  • SEAROC cancer center,S.K.soni Hospital
    Jaipur, Rajasthan, 302013, India
  • Birla Cancer Centre
    Jaipur, 302004, India

Showing the first 100 of 210 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Heigener DF, Krzakowski M, Mellemgaard A, Novello S, Orlov S, Summers Y, von Pawel J, Stohr J, Kaiser R, Reck M. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Target Oncol. 2017 Aug;12(4):475-485. doi: 10.1007/s11523-017-0517-2. PubMed 28702806 ↗
  • Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S; LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9. PubMed 24411639 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Nov 2010, 22 months.

Results were first posted in Dec 2014, 4 years after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 22 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2008
First posted
Dec 9, 2008
StartActual
Dec 3, 2008
Primary completionActual
Nov 2, 2010
CompletionActual
Nov 13, 2017
Results first posted
Dec 1, 2014
Last update
Dec 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00805194
Responsible party
Sponsor
First posted
Dec 9, 2008
Start date
Dec 3, 2008
Primary completion
Nov 2, 2010
Completion
Nov 13, 2017
Results posted
Dec 1, 2014
Last update
Dec 5, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nintedanib · Docetaxel

Start the discussion